AIPAC-003: A randomized, double-blind, placebo-controlled phase 3 trial testing eftilagimod alpha (soluble LAG-3) in patients with HER2-neg/low metastatic breast cancer receiving paclitaxel, following an open-label dose optimization.

Authors

Nuhad K. Ibrahim

University of Texas MD Anderson Cancer Center, Houston, TX

Nuhad K. Ibrahim , Konstantinos Papadamitriou , Francois P. Duhoux , Serafin Morales Murillo , Mafalda Oliveira , Bernard Doger de Spéville , Danny Houtsma , Aart Beeker , Julio Antonio Peguero , Omkar Marathe , Frederic Triebel

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2019 ASCO Annual Meeting

bookmark_border

End-of-study analysis from the phase III, randomized, double-blind, placebo (Pla)-controlled CLEOPATRA study of first-line (1L) pertuzumab (P), trastuzumab (H), and docetaxel (D) in patients (pts) with HER2-positive metastatic breast cancer (MBC).

First Author: Sandra M. Swain

insert_chart_outlined

Poster

2018 ASCO Annual Meeting

bookmark_border

The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma.

First Author: Manish A. Shah

insert_chart_outlined

Poster

2014 ASCO Annual Meeting

bookmark_border

A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib in combination with bendamustine and rituximab for previously untreated chronic lymphocytic leukemia.

First Author: Gilles A. Salles

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

HER2CLIMB-05: Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer.

First Author: Erika P. Hamilton